Skip to Main Content

WASHINGTON — Regulators had something of an atypical message for the new nonprofit drug company backed by a host of the nation’s top hospitals: “What can we do to help?”

One of the executives behind the new drug maker, Civica Rx, told STAT he’d set up a Capitol Hill briefing after he fielded calls from roughly two dozen senators, all wanting to hear from the company about its plans. A meeting with the Food and Drug Administration also went far more smoothly than some industry tussles with their regulator.


“Basically the responses were, ‘What can we do to help you?’” Dan Liljenquist said of his meeting with the FDA about a month ago, adding that Civica is “really pleased with the response that we’ve had from regulators.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!